论文部分内容阅读
目的:探讨重组人干扰素α-1b联合高渗氯化钠溶液雾化治疗毛细支气管炎疗效。方法:120例毛细支气管炎患儿随机分为对照组和治疗组各60例,对照组给予常规综合治疗,治疗组在对照组基础上给予重组人干扰素α-1 b 20μg+0.9%氯化钠注射液3 ml联合高渗氯化钠溶液(0.9%氯化钠注射液2.5 ml+10%氯化钠注射液1.5 ml)加压雾化吸入,qd,疗程3～5 d。观察两组主要症状、体征消失时间及平均住院时间,以及两组治疗期间的不良反应发生情况。评价两组临床疗效。结果:治疗组在喘憋、呼吸困难、咳嗽、啰音等消失时间方面均优于对照组(P<0.05),总有效率也明显高于对照组(P<0.05)。结论:重组干扰素α-1b联合高渗氯化钠溶液雾化治疗毛细支气管炎有明显疗效。
Objective: To investigate the efficacy of recombinant human interferon α-1b combined with hypertonic sodium chloride solution in the treatment of bronchiolitis. Methods: A total of 120 children with bronchiolitis were randomly divided into control group and treatment group, 60 cases in each group. The control group was given conventional combination therapy. The treatment group was given recombinant interferon alfa-1 b 20μg + 0.9% chlorination Sodium injection 3 ml combined with hypertonic sodium chloride solution (0.9% sodium chloride injection 2.5 ml + 10% sodium chloride injection 1.5 ml) pressurized atomization inhalation, qd, treatment of 3 ~ 5 d. The main symptoms of the two groups were observed, the disappearance of signs and the average length of stay, and the incidence of adverse reactions in the two groups during treatment. Evaluation of two groups of clinical efficacy. Results: The treatment group was better than the control group (P <0.05) in asthma, dyspnea, cough, rales and other disappearance time, the total effective rate was also significantly higher than the control group (P <0.05). Conclusion: The treatment of bronchiolitis with recombinant interferon α-1b combined with hypertonic sodium chloride solution has obvious curative effect.